123016-21-7

Basic information

• Product Name: [S,(+)]-α-Methyl-6-(2-quinolinylmethoxy)-2-naphthaleneacetic acid
• Synonyms: [S,(+)]-α-Methyl-6-(2-quinolinylmethoxy)-2-naphthaleneacetic acid
• CAS NO: 123016-21-7
• Molecular Formula: C23H19NO3
• Molecular Weight: 357.40186
• Mol File: 123016-21-7.mol

Chemical Properties

• Boiling Point: 574.4°Cat760mmHg
• Flash Point: 301.2°C
• Appearance: /
• Density: 1.275g/cm³
• Vapor Pressure: 4.94E-14mmHg at 25°C
• Refractive Index: 1.688
• CAS DataBase Reference: [S,(+)]-α-Methyl-6-(2-quinolinylmethoxy)-2-naphthaleneacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: [S,(+)]-α-Methyl-6-(2-quinolinylmethoxy)-2-naphthaleneacetic acid(123016-21-7)
• EPA Substance Registry System: [S,(+)]-α-Methyl-6-(2-quinolinylmethoxy)-2-naphthaleneacetic acid(123016-21-7)

Safety Data

• Hazardous Substances Data: 123016-21-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-MNA is used as a nonsteroidal anti-inflammatory drug (NSAID) for its ability to inhibit the synthesis of prostaglandins, which are chemical messengers that play a role in the body's inflammatory response. This application makes it a potential candidate for the treatment of conditions such as rheumatoid arthritis and osteoarthritis.
Used in Neuroprotective Applications:
6-MNA is also recognized for its antioxidant and neuroprotective effects, which contribute to its potential use in the development of treatments for neurological disorders and conditions where oxidative stress and neurodegeneration are factors.
Used in Research and Development:
As a compound with multiple potential applications, 6-MNA is used in the research and development of new pharmaceuticals and therapies, particularly in the fields of pain management, inflammation, and neuroprotection. Its study may lead to the discovery of novel treatments and a deeper understanding of the underlying mechanisms of various diseases and conditions.

InChI:InChI=1/C23H19NO3/c1-15(23(25)26)17-6-7-19-13-21(11-9-18(19)12-17)27-14-20-10-8-16-4-2-3-5-22(16)24-20/h2-13,15H,14H2,1H3,(H,25,26)/t15-/m0/s1

Upstream product

• 4377-41-7 2-Chloromethylquinoline 
• 52079-10-4 (+)-6-O-Demethylnaproxen 

Relevant articles and documents

Quinolinylmethoxy naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents

There are disclosed compounds of the formula STR1 wherein R is hydrogen or lower alkyl; Y is STR2 or a pharmaceutically acceptable salt thereof, and its use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, in psoriasis, ulcerative colitis, rheumatoid arthritis as well as in other immediate hypersensitivity reactions.

Quinoline substituted naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents

There are disclosed compounds of the formula STR1 wherein a is alkyl 3-19 carbon atoms, diloweralkyl allyl, diahaloallyl, diphenylallyl, lower alkynyl, STR2 W is --CR2 O--, --CH=CH-- or --CH=CHCH2 O-- X is N or CR; Z is STR3 R is hydrogen or lower alkyl; Y is STR4 R1 is hydrogen, lower alkyl or phenyl; R2 is hydrogen or lower alkyl; or R1 and R2 taken together form a benzene ring, optionally substituted by halo; R3 is --OR, STR5 -- NHSO2 R4 ; R4 is phenyl or loweralkyl substituted phenyl; R5 is halo; and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as alelrgic rhinitis, allergic bronchial asthma and the like, in psoriasis, ulcerative colitis, rheumatoid arthritis as well as in other immediate hypersensitivity reactions.

Naphthalenepropionic acid derivatives as anti-inflammatory/anti-allergic agents

There are disclosed compounds of the formula STR1 wherein A is alkyl of 3-19 carbon atoms, diloweralkyl allyl, dihaloallyl, diphenylallyl, lower alkynyl, STR2 X is N or CR; Z is STR3 R is hydrogen or lower alkyl; R1 is hydrogen, lower alkyl or phenyl; R2 is hydrogen or loweralkyl; or R1 and R2 taken together form a benzene ring; and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, in psoriasis, ulcerative colitis, rheumatoid arthritis as well as in other immediate hypersensitivity reactions.